Table 2.
Approved unconjugated anti-cancer MAbs (as of 1 May 2020).
| Name | Target Antigen | Antibody Type a | First Indication | Year of First Approval b |
|---|---|---|---|---|
| Rituximab | CD20 | Chimeric IgG1k | B-NHL | 1997 (US) 1998 (EU) |
| Ofatumumab | CD20 | Human IgG1k | CLL | 2009 (US) 2010 (EU) |
| Obinutuzumab | CD20 | Humanized IgG1k; Glycoengin |
CLL | 2013 (US) 2014 (EU) |
| Trastuzumab | HER2 | Humanized IgG1k | Breast cancer | 1998 (US) 2000 (EU) |
| Pertuzumab | HER2 | Humanized IgG1k | Breast cancer | 2012 (US) 2013 (EU) |
| Cetuximab | EGFR | Chimeric IgG1k | CRC | 2004 (US/EU) |
| Panitumumab | EGFR | Human IgG2k | CRC | 2006 (US) 2007 (EU) |
| Necitumumab | EGFR | Human IgG1k | NSCLC | 2015 (US/EU) |
| Daratumumab | CD38 | Human IgG1k | MM | 2015 (US) 2016 (EU) |
| Isatuximab | CD38 | Chimeric IgG1k | MM | 2020 (US) |
| Alemtuzumab | CD52 | Humanized IgG1k | CLL | 2001 (US/EU) |
| Mogamulizumab | CCR4 | Humanized IgG1k | T leukemia/lymphoma | 2012 Japan 2018 EU |
| Elotuzumab | SLAMF7 | Humanized IgG1k | MM | 2015 (US) 2016 (EU) |
| Olaratumab | PDGRFα | Human IgG1k | Soft tissue sarcoma | 2016 (US/EU) |
| Dinutuximab-β | GD2 | Chimeric IgG1k | Neuroblastoma | 2015 (US/EU) |
| Ramucirumab | VEGFR2 | Human IgG1k | Gastric cancer | 2014 (US/EU) |
| Bevacizumab | VEGF | Humanized IgG1k | CRC | 2004 (US) 2005 (EU) |
| Tremelimumab | CTLA-4 | Human IgG2k | Melanoma | Orphan 2006 |
| Ipilimumab | CTLA-4 | Human IgG1k | Melanoma | 2011 (US/EU) |
| Nivolumab | PD-1 | Human IgG4k S228P | Melanoma + Solid cancer | 2014 (US) 2015 (EU) |
| Pembrolizumab | PD-1 | Humanized IgG4k S228P | Melanoma + Solid cancer + HL + PMBCL | 2014 (US) 2015 (EU) |
| Cemiplimab | PD-1 | Human IgG4k S228P | Cutaneous squamous cell carcinoma | 2018 (US) 2019 (EU) |
| Avelumab | PD-L1 | Human IgG1k | MC, UC, RCC | 2017 (US/EU) |
| Atezolizumab | PD-L1 | Humanized IgG1k mut | UC, NSCLC | 2016 (US) 2017 (EU) |
| Durvalumab | PD-L1 | Human IgG1k mut | NSCLC | 2017 (US) 2018 (EU) |
a IgG4 S228P has mutations to avoid heavy chain exchange; IgG1k mut antibodies have a mutation that render the Fc silent. b US Federal Drug Administration (FDA) and/or European Medicines Agency (EMA) approval.